---
figid: PMC5382109__nihms824859f6
figlink: /pmc/articles/PMC5382109/figure/F6/
number: Figure 6
caption: 'Therapeutic targets in B cell lymphoma of NF-κB activation. The pathogenesis
  of B cell lymphoma activation involves constitutive activation of BCR, MyD88, and
  NF-κB pathway promoting cell survival through NF-κB signaling pathways. Small molecule
  inhibitor is designed to target specific signals in these complex networks to inhibit
  NF-κB in B cell lymphomas, including: (1), SYK (Fostamatinib/R406). (2), BTK (Ibrutinib;
  Acalabrutinib). (3), PKCb (Enzastaurin). (4), IKK (MLN120B). (5), HSP90 (KW-2478;
  SNX-7081). (6), proteasome (Bortezomib). (7), NEDD8-activating enzyme (MLN4924).
  (8), IRAK4 (RNAi). (9), Src-family kinase (Dasatinib).'
pmcid: PMC5382109
papertitle: NF-κB Signaling Pathway and its Potential as a Target for Therapy in Lymphoid
  Neoplasms.
reftext: Li Yu, et al. Blood Rev. ;31(2):77-92.
pmc_ranked_result_index: '53933'
pathway_score: 0.9621745
filename: nihms824859f6.jpg
figtitle: Therapeutic targets in B cell lymphoma of NFKB activation
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5382109__nihms824859f6.html
  '@type': Dataset
  description: 'Therapeutic targets in B cell lymphoma of NF-κB activation. The pathogenesis
    of B cell lymphoma activation involves constitutive activation of BCR, MyD88,
    and NF-κB pathway promoting cell survival through NF-κB signaling pathways. Small
    molecule inhibitor is designed to target specific signals in these complex networks
    to inhibit NF-κB in B cell lymphomas, including: (1), SYK (Fostamatinib/R406).
    (2), BTK (Ibrutinib; Acalabrutinib). (3), PKCb (Enzastaurin). (4), IKK (MLN120B).
    (5), HSP90 (KW-2478; SNX-7081). (6), proteasome (Bortezomib). (7), NEDD8-activating
    enzyme (MLN4924). (8), IRAK4 (RNAi). (9), Src-family kinase (Dasatinib).'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IKBKB
  - FOS
  - NFKBIA
  - CHUK
  - PRKCB
  - CD79B
  - SYK
  - IKBKG
  - BTK
  - BCR
  - MYD88
  - TNFAIP3
  - IK
  - LYN
  - IL1R1
  - MALT1
  - NFKB1
  - Ibrutinib
genes:
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKB
  entrez: '3551'
- word: Fos
  symbol: FOS
  source: hgnc_symbol
  hgnc_symbol: FOS
  entrez: '2353'
- word: IKBa
  symbol: IkappaBalpha
  source: hgnc_alias_symbol
  hgnc_symbol: NFKBIA
  entrez: '4792'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: CHUK
  entrez: '1147'
- word: PKCB
  symbol: PKCB
  source: hgnc_prev_symbol
  hgnc_symbol: PRKCB
  entrez: '5579'
- word: IKKB
  symbol: IKK-beta
  source: hgnc_alias_symbol
  hgnc_symbol: IKBKB
  entrez: '3551'
- word: CD79b
  symbol: CD79B
  source: hgnc_symbol
  hgnc_symbol: CD79B
  entrez: '974'
- word: SYK
  symbol: SYK
  source: hgnc_symbol
  hgnc_symbol: SYK
  entrez: '6850'
- word: IKK
  symbol: IKK
  source: bioentities_symbol
  hgnc_symbol: IKBKG
  entrez: '8517'
- word: BTK
  symbol: BTK
  source: hgnc_symbol
  hgnc_symbol: BTK
  entrez: '695'
- word: BCR
  symbol: BCR
  source: hgnc_symbol
  hgnc_symbol: BCR
  entrez: '613'
- word: MYD88
  symbol: MYD88
  source: hgnc_symbol
  hgnc_symbol: MYD88
  entrez: '4615'
- word: A20
  symbol: A20
  source: hgnc_alias_symbol
  hgnc_symbol: TNFAIP3
  entrez: '7128'
- word: IK
  symbol: IK
  source: hgnc_symbol
  hgnc_symbol: IK
  entrez: '3550'
- word: Lyn
  symbol: LYN
  source: hgnc_symbol
  hgnc_symbol: LYN
  entrez: '4067'
- word: IL-1R
  symbol: IL1R
  source: hgnc_prev_symbol
  hgnc_symbol: IL1R1
  entrez: '3554'
- word: MALT1
  symbol: MALT1
  source: hgnc_symbol
  hgnc_symbol: MALT1
  entrez: '10892'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
chemicals:
- word: Ibrutinib
  source: MESH
  identifier: C551803
diseases: []
---
